Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376839" target="_blank" >RIV/00216208:11110/18:10376839 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00104655 RIV/61988987:17110/18:A1901ZA4 RIV/00216208:11150/18:10376839 RIV/65269705:_____/18:00070311 a 3 dalších

Výsledek na webu

<a href="https://doi.org/10.1016/j.clml.2018.04.003" target="_blank" >https://doi.org/10.1016/j.clml.2018.04.003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clml.2018.04.003" target="_blank" >10.1016/j.clml.2018.04.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

Popis výsledku v původním jazyce

The Registry of Monoclonal Gammopathies (RMG) collects long-term data for patients with hematologic malignancies and is one of the largest registries of its type in Europe. The present noninterventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into the real-world treatment outcomes of patients with multiple myeloma. Introduction: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. Materials and Methods: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. Results: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (&lt;= 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. Conclusion: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.

Název v anglickém jazyce

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

Popis výsledku anglicky

The Registry of Monoclonal Gammopathies (RMG) collects long-term data for patients with hematologic malignancies and is one of the largest registries of its type in Europe. The present noninterventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into the real-world treatment outcomes of patients with multiple myeloma. Introduction: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. Materials and Methods: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. Results: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (&lt;= 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. Conclusion: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lymphoma, Myeloma &amp; Leukemia

ISSN

2152-2650

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

22

Strana od-do

"E219"-"E240"

Kód UT WoS článku

000432995800001

EID výsledku v databázi Scopus

2-s2.0-85047298566